Nuvectra Corporation (NVTR)
(Delayed Data from NSDQ)
$6.14 USD
+0.01 (0.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.13 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.14 USD
+0.01 (0.16%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.13 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Nuvectra (NVTR) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study
by Zacks Equity Research
Axonics (AXNX) expects to improve performance on the positive outcome of the study.
Nuvectra (NVTR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nuvectra (NVTR) delivered earnings and revenue surprises of 23.46% and -0.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nuvectra (NVTR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nuvectra (NVTR) delivered earnings and revenue surprises of -27.69% and -12.79%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Nuvectra (NVTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nuvectra (NVTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nuvectra (NVTR) delivered earnings and revenue surprises of -1.16% and 14.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Nuvectra (NVTR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nuvectra (NVTR) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Nuvectra (NVTR) Stock?
by Zacks Equity Research
Investors in Nuvectra (NVTR) need to pay close attention to the stock based on moves in the options market lately.
Nuvectra (NVTR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nuvectra (NVTR) delivered earnings and revenue surprises of 9.78% and 13.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
by Zacks Equity Research
There are some powerful long-term tailwinds in the medical space.